Kari Ferver
Overview
Kari effectively represents clients in complex and fast-paced antitrust and litigation matters, particularly in the healthcare space. She works closely with clients and colleagues to assess difficult and novel legal issues and craft associated strategies. Kari regularly drafts substantive motions and complaints; prepares corporate representatives for depositions; and communicates with clients about litigation developments and industry updates.
Career & Education
- University of California, Irvine, B.A., summa cum laude, Criminology, Law & Society, 2006
- University of California, Irvine, M.A., Social Ecology, 2009
- University of California, Irvine School of Law, J.D., summa cum laude, 2021
- California
Kari's Insights
Client Alert | 4 min read | 09.02.26
Enbrel (etanercept) is one of the best-selling biologic drugs in the United States, approved to treat rheumatoid arthritis and other serious inflammatory conditions. Etanercept was launched as Enbrel in 1998 as a treatment for moderate to severe rheumatoid arthritis, and was later approved to treat additional inflammatory diseases including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
Blog Post | 05.13.26
Blog Post | 03.04.26
Press Coverage | 01.05.26
Huntington Beach housing fight signals stronger state enforcement of planning law
Insights
Huntington Beach housing fight signals stronger state enforcement of planning law
|01.05.26
Daily Journal
FTC Blog Updates (May 3 - 8, 2026)
|05.13.26
Crowell & Moring's Retail & Consumer Products Law Observer
FTC Updates (December 8 – 12, 2025)
|12.22.25
Crowell & Moring’s Retail & Consumer Products Law Observer
FTC Updates (August 4 –August 22, 2025)
|09.12.25
Crowell & Moring’s Retail & Consumer Products Law Observer
FTC Updates (June 16 – 20, 2025)
|06.30.25
Crowell & Moring’s Retail & Consumer Products Law Observer
Ninth Circuit Affirms that CIPA Only Applies to Third-Party Eavesdropping
|06.27.25
Crowell & Moring’s Retail & Consumer Products Law Observer
Appellate Guidance Needed on California Chatbot Litigation
|06.10.25
Crowell & Moring’s State AG Blog
FTC Updates (April 14 – 18, 2025)
|04.29.25
Crowell & Moring’s Retail & Consumer Products Law Observer
Taking Aim at Humphrey’s Executor: Trump Fires the FTC’s Democratic Commissioners
|03.19.25
Crowell & Moring’s Retail & Consumer Products Law Observer
FTC Updates (February 3- 21, 2025)
|03.17.25
Crowell & Moring’s Retail & Consumer Products Law Observer
Kari's Insights
Client Alert | 4 min read | 09.02.26
Enbrel (etanercept) is one of the best-selling biologic drugs in the United States, approved to treat rheumatoid arthritis and other serious inflammatory conditions. Etanercept was launched as Enbrel in 1998 as a treatment for moderate to severe rheumatoid arthritis, and was later approved to treat additional inflammatory diseases including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
Blog Post | 05.13.26
Blog Post | 03.04.26
Press Coverage | 01.05.26
Huntington Beach housing fight signals stronger state enforcement of planning law




